
MEI Pharma MEIP
MEI Pharma ROCE Ratio | MEIP
Annual ROCE Ratio MEI Pharma
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -159.95 | -103.09 | 44.04 | -36.59 | -49.21 | -39.27 | -13.11 | -67.65 | -29.54 | 4.69 | -50.43 | -54.81 | -60.25 | -32.18 | -182.52 | -359.59 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 44.04 | -359.59 | -74.34 |
Quarterly ROCE Ratio MEI Pharma
| 2027-Q1 | 2026-Q4 | 2026-Q3 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.6 | -69.22 | -105.71 | -71.01 | -111.5 | -113.25 | -93.68 | -30.7 | 14.9 | 98.79 | 122.86 | 15.5 | 16.82 | -63.77 | -80.35 | -45.64 | -45.14 | -42.52 | -41.74 | -35.26 | -19.34 | -23.72 | -27.52 | -42.46 | -65.5 | -68.12 | -69.54 | -59.24 | -49.78 | -40.0 | -33.2 | -31.57 | -32.58 | -26.54 | 1.46 | -9.41 | -14.66 | -22.22 | -52.69 | -42.67 | -37.27 | -36.8 | -35.84 | -33.23 | -44.83 | -60.47 | -72.07 | -84.22 | -82.25 | -74.08 | -72.11 | -66.27 | -107.99 | -182.72 | -208.95 | -248.48 | -238.4 | -205.52 | -377.92 | -432.04 | -57.62 | -216.83 | -107.75 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 122.86 | -432.04 | -72.02 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Lyra Therapeutics
LYRA
|
289.47 | - | - | $ 24.9 M | ||
|
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-175.6 | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
-29.63 | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
74.33 | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-41.99 | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-71.67 | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-92.11 | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-17.17 | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
9.07 | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-5.84 | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-68.09 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-25.89 | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-134.09 | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-46.52 | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-1610.96 | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-106.49 | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-60.71 | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-69.47 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-235.23 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-36.31 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-53.23 | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
11.01 | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-141.76 | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-96.98 | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-106.57 | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
458.12 | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
1322.0 | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
166.56 | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
102.23 | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-242.78 | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-194.9 | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-71.49 | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-59.84 | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-111.56 | - | - | $ 728 M |